De novo combined lamivudine and adefovir dipivoxil therapy vs entecavir monotherapy for hepatitis B virus-related decompensated cirrhosis

Table 2 Comparison of changes in hepatic function

Characteristics	LAM + ADV combination group			ETV monotherapy group
	0 wk	48 wk	96 wk	0 wk	48 wk	96 wk
Alb (g/L)	29.2 ± 0.7	32.2 ± 0.5	36.7 ± 0.2a	28.9 ± 1.2	31.9 ± 0.4	36.4 ± 0.6a
TBil (μmol/L)	51.6 ± 8.9	30.8 ± 7.5	19.1 ± 6.2a	47.2 ± 6.8	31.6 ± 6.8	18.2 ± 3.9a
ALT (U/L)	98.1 ± 21.6	56.1 ± 21.3	34.7 ± 12.8a	99.8 ± 17.2	54.2 ± 15.7	32.5 ± 11.5a
PT (s)	16.3 ± 2.3	14.3 ± 1.6	12.6 ± 2.1a	16.5 ± 1.9	13.8 ± 2.0	12.9 ± 3.7a
CTP score	8.4 ± 1.7	6.8 ± 1.9	5.5 ± 3.7a	8.6 ± 2.1	6.7 ± 2.5	5.7 ± 1.3a
MELD score	13.7 ± 3.5	9.8 ± 3.1	7.6 ± 1.8a	12.9 ± 6.7	9.6 ± 4.3	7.9 ± 2.3a

^aP < 0.05 vs baseline. ALT: Alanine aminotransferase; TBil: Total bilirubin; Alb: Albumin; PT: Prothrombin time: CTP: Child-Turcotte-Pugh; MELD: Model for end-stage liver disease; LAM: Lamivudine; ADV: Adefovir dipivoxil; ETV: Entecavir.